| Year |
Citation |
Score |
| 2023 |
Shah SD, Gillard BM, Wrobel MM, Karasik E, Moser MT, Mastri M, Long MD, Sule N, Brackett CM, Huss WJ, Foster BA. Syngeneic model of carcinogen-induced tumor mimics basal/squamous, stromal-rich, and neuroendocrine molecular and immunological features of muscle-invasive bladder cancer. Frontiers in Oncology. 13: 1120329. PMID 36816919 DOI: 10.3389/fonc.2023.1120329 |
0.336 |
|
| 2022 |
Ivanick NM, Oakley ER, Kunadharaju R, Brackett C, Bellnier DA, Tworek LM, Kurenov SN, Gollnick SO, Hutson AD, Busch TM, Shafirstein G. First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies. Jto Clinical and Research Reports. 3: 100372. PMID 36188632 DOI: 10.1016/j.jtocrr.2022.100372 |
0.596 |
|
| 2021 |
Chen M, Brackett CM, Burdelya LG, Punnanitinont A, Patnaik SK, Matsuzaki J, Odunsi AO, Gudkov AV, Singh AK, Repasky EA, Gurova KV. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy. Cancer Immunology, Immunotherapy : Cii. PMID 33439292 DOI: 10.1007/s00262-020-02846-8 |
0.488 |
|
| 2020 |
Haderski GJ, Kandar BM, Brackett CM, Toshkov IM, Johnson CP, Paszkiewicz GM, Natarajan V, Gleiberman AS, Gudkov AV, Burdelya LG. TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. Plos One. 15: e0227940. PMID 32027657 DOI: 10.1371/Journal.Pone.0227940 |
0.459 |
|
| 2017 |
Mett V, Komarova EA, Greene K, Bespalov I, Brackett C, Gillard B, Gleiberman AS, Toshkov IA, Aygün-Sunar S, Johnson C, Karasik E, Bapardekar-Nair M, Kurnasov OV, Osterman AL, Stanhope-Baker PS, et al. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene. PMID 28967901 DOI: 10.1038/Onc.2017.346 |
0.555 |
|
| 2016 |
Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proceedings of the National Academy of Sciences of the United States of America. PMID 26831100 DOI: 10.1073/Pnas.1521359113 |
0.654 |
|
| 2016 |
Brackett C, Kojouharov B, Gollnick S, Gudkov A, Burdelya L. Abstract B090: A Toll-like receptor 5 agonist entolimod as a potential anticancer immunotherapeutic agent Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B090 |
0.674 |
|
| 2015 |
Yang H, Brackett CM, Morales-Tirado VM, Li Z, Zhang Q, Wilson MW, Benjamin C, Harris W, Waller EK, Gudkov AV, Burdelya LG, Grossniklaus HE. The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget. PMID 26655090 DOI: 10.18632/Oncotarget.6500 |
0.466 |
|
| 2014 |
Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, Gleiberman AS, Gudkov AV, Burdelya LG. Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget. 5: 802-14. PMID 24583651 DOI: 10.18632/Oncotarget.1773 |
0.413 |
|
| 2013 |
Brackett CM, Muhitch JB, Evans SS, Gollnick SO. IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. Journal of Immunology (Baltimore, Md. : 1950). 191: 4348-57. PMID 24026079 DOI: 10.4049/Jimmunol.1103621 |
0.601 |
|
| 2013 |
Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, et al. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proceedings of the National Academy of Sciences of the United States of America. 110: E1857-66. PMID 23630282 DOI: 10.1073/Pnas.1222805110 |
0.451 |
|
| 2011 |
Brackett CM, Owczarczak B, Ramsey K, Maier PG, Gollnick SO. IL-6 potentiates tumor resistance to photodynamic therapy (PDT). Lasers in Surgery and Medicine. 43: 676-85. PMID 22057495 DOI: 10.1002/Lsm.21107 |
0.677 |
|
| 2011 |
Brackett CM, Gollnick SO. Photodynamic therapy enhancement of anti-tumor immunity. Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society For Photobiology. 10: 649-52. PMID 21253659 DOI: 10.1039/C0Pp00354A |
0.679 |
|
| 2010 |
Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunologic Research. 46: 216-26. PMID 19763892 DOI: 10.1007/S12026-009-8119-4 |
0.677 |
|
| Show low-probability matches. |